Australia's Biota merges with Nabi for cash and exposure to larger US investment market
This article was originally published in Scrip
Executive Summary
Australian firm Biota Holdings is to merge with Maryland-based Nabi Biopharmaceuticals and relocate to the US in a deal that is aimed at bringing Biota fresh funds, greater liquidity and a chance to move beyond its royalty-based revenue model.